Oncology drug development

HORSHAM, Pennsylvania – March 5, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration has approved...

HOUSTON, Texas — March 4, 2026 BrYet US, Inc., a biotechnology company focused on developing innovative cancer therapies, announced...

PUNE, India, February 26, 2026 The global head and neck cancer therapeutics market is projected to grow from USD...

WALTHAM, Mass. & SHANGHAI, Feb. 2, 2026 — Ensem Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, announced that it...

BOSTON and DAEJEON, South Korea, Jan. 4, 2026 — Orum Therapeutics, a biotechnology company pioneering degrader-antibody conjugates (DACs), announced...

NEW YORK, December 29, 2025 — SELLAS Life Sciences Group has provided a key update on its pivotal Phase...

CHICAGO, USA | December 24, 2025 — MAIA Biotechnology, a clinical-stage biopharmaceutical company focused on targeted immuno-oncology, announced that...

LONDON and PHILADELPHIA, December 17, 2025 — Avacta Therapeutics, a clinical-stage biopharmaceutical company, has reported positive Phase 1b clinical...

INDIANAPOLIS, Sept. 4, 2025 – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib,...

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has...